To include your compound in the COVID-19 Resource Center, submit it here.

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 4/17 cls
Akebia Therapeutics Inc. (NASDAQ:AKBA) UBS Matthew Roden New Buy 55% $26.09
Roden initiated coverage with a $28 target on the belief that Akebia's AKB-6548

Read the full 511 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE